Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
PremiumPress ReleasesInozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
1M ago
Inozyme reports Q2 EPS (44c), consensus (39c)
Premium
The Fly
Inozyme reports Q2 EPS (44c), consensus (39c)
1M ago
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
Premium
Press Releases
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
2M ago
Inozyme initiated with an Overweight at Wells Fargo
PremiumThe FlyInozyme initiated with an Overweight at Wells Fargo
4M ago
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
Premium
Press Releases
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
4M ago
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
Premium
Press Releases
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
4M ago
Inozyme reports inducement grants under Nasdaq listing rule
PremiumThe FlyInozyme reports inducement grants under Nasdaq listing rule
5M ago
Inozyme management to meet with Piper Sandler
Premium
The Fly
Inozyme management to meet with Piper Sandler
5M ago
Inozyme management to meet with Piper Sandler
Premium
The Fly
Inozyme management to meet with Piper Sandler
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100